FDA Is Not a Passport: The Board-Level Questions US Medtech Founders Must Answer Before Japan
Photo: Syced, CC0, via Wikimedia Commons
A US medtech founder who has cleared the FDA can be forgiven for assuming that Japan is the next logical market. The product has already survived a rigorous review. The clinical evidence exists. The quality system is in place. Why should Japan be different?
The answer is that FDA clearance is a domestic milestone, not a global passport. Japan's Pharmaceuticals and Medical Devices Agency, known as the PMDA, operates within a different regulatory system, and reimbursement decisions sit in a separate process that can determine commercial viability. For founders and boards, the danger is not that Japan is uniquely difficult. The danger is that the company treats Japan as an administrative extension of its US approval.
FDA Clearance Is a Domestic Milestone
The FDA and the PMDA share a commitment to safety and efficacy, but they do not ask identical questions or rely on identical evidence. A US 510(k) clearance may rest on substantial equivalence to a predicate device. A PMDA review may require a different predicate analysis, additional clinical data, or a bridging study that reflects Japanese clinical practice.
This matters at the board level because regulatory strategy drives budget, timeline, and partner selection. If the company assumes that a translated FDA submission will suffice, it may underfund the Japanese program and discover the gap only after months of preparation. A board that approves Japan entry without a clear regulatory map is not making a market-entry decision. It is accepting an unmeasured risk.
What PMDA Actually Reviews
PMDA review is not a single event. It involves classification of the device, selection of the approval pathway, assessment of clinical evidence, and confirmation of quality management systems. The company must identify a Japanese predicate or equivalent device where applicable, determine whether clinical trials in Japan are needed, and prepare for post-market surveillance obligations.
The practical question for a US founder is not whether the FDA data are strong. The question is whether those data answer the questions Japanese reviewers will ask. Sometimes they do. Sometimes the company needs additional clinical evidence, a local clinical site, or a more detailed risk-benefit analysis. Those requirements should be identified before the company commits to a filing date.
Boards should ask management for a written regulatory gap assessment. It should state the proposed approval route, the evidence already available, the evidence still missing, the expected review timeline, and the cost of closing the gap. Without that document, the Japan program is difficult to govern.
Reimbursement Is the Commercial Gate
Even a successful PMDA approval does not guarantee that hospitals will be paid for using the device. Japan's reimbursement system sets prices and categories through a separate process. The timing of a reimbursement decision can shape the entire commercial model.
A device may be approved and still fail commercially if reimbursement is delayed, restricted, or priced below the company's assumptions. US medtech founders often focus on regulatory approval because it is familiar. Japanese partners, however, will want to know how the product will be reimbursed, which clinical specialties will support it, and what evidence health economic reviewers will expect.
The board should require a reimbursement plan before the filing strategy is finalized. That plan should identify the relevant reimbursement category, the expected timeline, the clinical and economic evidence needed, and the partner responsible for the submission. If reimbursement is treated as a post-approval task, the company may spend millions on approval and still lack a viable market.
Partner Selection Before Filing
Choosing a Japanese partner after approval is late. The right partner can help shape the regulatory pathway, identify clinical sites, prepare reimbursement arguments, and build relationships with opinion leaders. The wrong partner can delay the program or push the company toward a distribution arrangement that captures value without contributing to regulatory success.
Boards should assess potential partners on regulatory affairs capability, therapeutic-area fit, sales force reach, commitment to the product, and willingness to accept defined milestones. Governance terms matter: who owns the regulatory submission, who controls clinical data, who bears the cost of additional studies, and how the relationship can be terminated. A partner who only wants distribution rights may be useful later, but that is not the same as a regulatory partner.
A Board-Level Regulatory Dashboard
Japan entry should be governed through a small set of board-level metrics. These include the approval route, the evidence gap, the reimbursement pathway, partner milestones, budget versus actual spend, and timeline risk. The board should also identify an executive sponsor who is accountable for Japan, rather than leaving the program buried inside regulatory affairs.
A quarterly review is usually sufficient, but the review must be substantive. It should test assumptions, not merely receive updates. If the evidence gap is widening or the reimbursement pathway is unclear, the board should be willing to slow the program. Speed without a clear regulatory and reimbursement map is not progress.
The Governance Lesson
Japan can be an attractive market for US medtech companies, but it is not an automatic extension of FDA success. The PMDA asks different questions, reimbursement follows its own calendar, and partner selection shapes both. Founders who understand this early make better decisions. Boards that treat Japan as a board-level risk rather than a regulatory formality are more likely to approve the right program, with the right budget, at the right time.